Repligen | RGEN - Interest Expense On Debt


Repligen reported $5.71M in Interest Expense on Debt for its fiscal quarter ending in September of 2026.





Interest Expense On Debt Change Date
Agilent USD 29M 4M Jun/2026
Align Technology USD 9.96M 3.02M Jun/2026
Bio Techne USD 2.17M 1.43M Sep/2026
BioMarin Pharmaceutical USD 55.63M 7.67M Sep/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
Bruker USD 17.8M 9.7M Jun/2026
Charles River Laboratories USD 28.52M 1.82M Sep/2026
Danaher USD 135M 28M Sep/2026
Dentsply International USD 27M 5M Sep/2026
General Electric Aerospace USD 231M 265M Sep/2026
Henry Schein USD 42M 1000K Sep/2026
Illumina USD 24M 0 Sep/2026
IQVIA Holdings USD 203M 6M Sep/2026
Mettler Toledo International USD 15.68M 1.57M Sep/2026
Myriad Genetics USD 4.4M 600K Dec/2025
OraSure Technologies 1.67M 1.13M Dec/2025
Pacific Biosciences Of California USD 1.74M 1000 Dec/2025
Pfizer USD 662M 5M Sep/2026
Repligen USD 5.71M 49K Sep/2026
Revvity USD 20.81M 2.18M Sep/2026
Standard Biotools USD 5K 5K Dec/2025
Thermo Fisher Scientific USD 417M 63M Sep/2026
Waters USD 53M 2M Sep/2026
West Pharmaceutical Services USD 3.8M 1.2M Sep/2026